Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Safaa Ramadan"'
Autor:
Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D. Smith
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
This multicenter, open-label, phase 1b study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naive (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients received acal
Externí odkaz:
https://doaj.org/article/19f79693265c45379007ce9489c9f51a
Autor:
Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chaun Wun, Wojciech Jurczak, Stephen D. Smith
Publikováno v:
HemaSphere, Vol 7, p e64204bc (2023)
Externí odkaz:
https://doaj.org/article/9deca2e7432f412095e2700752fdea94
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0283392 (2023)
Background and aimVitamin D deficiency is widespread worldwide and associated with negative effects on maternal and neonatal health. This study aimed to evaluate the relationship between vitamin D and thyroid and parathyroid hormone levels in the fir
Externí odkaz:
https://doaj.org/article/2fdff57697cc4a7dbc72e8c6ac0184f5
Autor:
Stefano Fiori, Elisabetta Todisco, Safaa Ramadan, Federica Gigli, Patrizia Falco, Alessandra Iurlo, Cristiano Rampinelli, Giorgio Croci, Stefano A. Pileri, Corrado Tarella
Publikováno v:
Biology, Vol 10, Iss 2, p 152 (2021)
Tyrosine kinase inhibitors (TKIs) are the treatment of choice for BCR-ABL1-positive chronic myeloid leukemia (CML). Although TKIs have substantially improved prognosis of CML patients, their use is not free of adverse effects. Dasatinib is a second g
Externí odkaz:
https://doaj.org/article/9ec56097edfc4b2090c83cebb315c23c
Autor:
Lindsay M. Morton, Anthony J. Swerdlow, Michael Schaapveld, Safaa Ramadan, David C. Hodgson, John Radford, Flora E. van Leeuwen
Publikováno v:
EJC Supplements, Vol 12, Iss 1, Pp 5-17 (2014)
Currently, 17–19% of all new primary malignancies occur in survivors of cancer, causing substantial morbidity and mortality. Research has shown that cancer treatments are important contributors to second malignant neoplasm (SMN) risk. In this paper
Externí odkaz:
https://doaj.org/article/5fb60fdc47c74e63aba8603e8c1e94bd
Autor:
Mwafy, Saleh Nazmy1 (AUTHOR) smwafy@hotmail.com, Abed El- Nabi, Safaa Ramadan1 (AUTHOR), Laqqan, Mohammed Marwan2 (AUTHOR), Yassin, Maged Mohamed3 (AUTHOR)
Publikováno v:
PLoS ONE. 3/30/2023, Vol. 17 Issue 3, p1-10. 10p.
Autor:
Saveria Mazzara, Laura Travaini, Francesca Botta, Chiara Granata, Giovanna Motta, Federica Melle, Stefano Fiori, Valentina Tabanelli, Anna Vanazzi, Safaa Ramadan, Tommaso Radice, Sara Raimondi, Giuliana Lo Presti, Mahila E. Ferrari, Barbara Alicja Jereczek-Fossa, Corrado Tarella, Francesco Ceci, Stefano Pileri, Enrico Derenzini
Publikováno v:
Blood Advances. 7:630-643
Emerging evidence indicates that chemoresistance is closely related to altered metabolism in cancer. Here, we hypothesized that distinct metabolic gene expression profiling (GEP) signatures might be correlated with outcome and with specific fluorodeo
Publikováno v:
Expert Review of Hematology. 15:295-304
Primary CNS lymphoma (PCNSL) has traditionally been treated with induction HD-MTX-based chemotherapy, followed by consolidation whole-brain radiotherapy. However, this approach is associated with significant neurocognitive complications, especially i
Publikováno v:
Tanta Scientific Nursing Journal; 2023 Supplement, Vol. 31, p169-190, 22p
Publikováno v:
Egyptian Journal of Health Care. 12:1806-1824